Page 8 - Tim Dyer News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex Increases Issued Share Capital to Create Treasury Shares Addex TherapeuticsApril 26, 2021 GMT Geneva, Switzerland, April 26, 2021 - Addex Therapeutics  Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has increased its share capital from 39,748,635 to 49,272,952 through the i...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex to Participate at the 4ᵗʰ Annual Neuroscience Innovation Forum Addex TherapeuticsApril 26, 2021 GMT Geneva, Switzerland, April 26, 2021 - Addex Therapeutics  Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will present at the 4ᵗʰ Annual...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex Reports Full Year 2020 Financial Results and Provides Corporate Update Addex TherapeuticsMarch 11, 2021 GMT Strong cash and cash equivalents position at Dec 31, 2020 of $20.2M (CHF18.7M) Balance sheet further strengthened by $11.5M fundraising on January 11, 2021 Three clinical studies in neurology programs expected to start during H1 2021 Clinical stage neurology programs aimed at large underse...

About Addex Therapeutics: Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addexs allosteric modu...

Indiana Gov. Eric Holcomb, a Republican, used an executive order to institute a mask mandate that took effect July 27. The blowback was almost instantaneous.

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder Addex TherapeuticsFebruary 16, 2021 GMT Review from Linköping University Published in Alcohol and Alcoholism Journal Geneva, Switzerland, February 16, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and developm...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex to Present at the Baader Helvea Swiss Equities Conference Addex TherapeuticsJanuary 12, 2021 GMT Geneva, Switzerland, January 12, 2021 -   Addex Therapeutics  Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, is scheduled to participate in the...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of ... Addex TherapeuticsJanuary 11, 2021 GMT Geneva, Switzerland, January 11, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the successful completion of the previously announce...

Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

Share: Geneva, Switzerland, December 14, 2020 – Addex Therapeutics Ltd (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for a proposed underwritten public offering of shares, including those to be settled in the form of American Depositary Shares (ADSs). Each ADS represents the right to receive six shares ...